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Abstract: Tuberculosis (TB) and HIV co-infections place
an immense burden on health care systems and pose
particular diagnostic and therapeutic challenges. Infection
with HIV is the most powerful known risk factor
predisposing for Mycobacterium tuberculosis infection
and progression to active disease, which increases the
risk of latent TB reactivation 20-fold. TB is also the most
common cause of AIDS-related death. Thus, M. tubercu-
losis and HIV act in synergy, accelerating the decline of
immunological functions and leading to subsequent
death if untreated. The mechanisms behind the break-
down of the immune defense of the co-infected individual
are not well known. The aim of this review is to highlight
immunological events that may accelerate the develop-
ment of one of the two diseases in the presence of the co-
infecting organism. We also review possible animal
models for studies of the interaction of the two
pathogens, and describe gaps in knowledge and needs
for future studies to develop preventive measures against
the two diseases.
Introduction
Tuberculosis (TB) and human immunodeficiency virus/ac-
quired immune deficiency syndrome (HIV/AIDS) constitute the
main burden of infectious disease in resource-limited countries.
Estimates by the World Health Organization (WHO) indicate that
there are more than 9 million new active cases of TB and close to 2
million deaths per year [1], and that 2.6 million new cases of HIV
infection and 1.8 million AIDS-related deaths occur per year [2].
Mycobacterium tuberculosis–HIV co-infections pose particular diag-
nostic and therapeutic challenges and exert immense pressure on
health care systems in African and Asian countries with large
populations of co-infected individuals
In the individual host the two pathogens, M. tuberculosis and
HIV, potentiate one another, accelerating the deterioration of
immunological functions and resulting in premature death if
untreated. Some 14 million individuals worldwide are estimated to
be dually infected [3]. TB is the largest single cause of death in the
setting of AIDS [4], accounting for about 26% of AIDS-related
deaths [3], 99% of which occur in developing countries [5].
Both TB and HIV have profound effects on the immune system,
as they are capable of disarming the host’s immune responses
through mechanisms that are not fully understood. HIV co-
infection is the most powerful known risk factor for progression of
M. tuberculosis infection to active disease, increasing the risk of
latent TB reactivation 20-fold [3,6]. Likewise, TB has been
reported to exacerbate HIV infection [7,8]. Various lines of
evidence indicate that inborn errors of immunity, as well as genetic
polymorphisms, have an impact on susceptibility to TB and HIV
[9].
Aspects of Immune Response to M. tuberculosis
Infection
M. tuberculosis infects the host mainly through inhalation of
aerosolized bacilli; alveolar macrophages are the primary target
cells for this intracellular pathogen. Detection of M. tuberculosis by
innate cells recognizing pathogen-associated molecular patterns,
via toll-like receptors (TLRs) and nucleotide-binding oligomer-
ization domain receptors, initiates a local inflammatory response
and results in increased numbers of macrophages and dendritic
cells (DCs) in infected lung tissue and draining pulmonary lymph
nodes. Following activation by cytokines and innate receptor
agonists, infected macrophages elicit direct bactericidal effector
functions, such as reactive oxygen or nitrogen intermediates
[10,11], or expression of small GTPases that can regulate
endosomal trafficking [12]. DCs can phagocytose the bacteria in
lung tissue, migrate to draining lymph nodes, and initiate the
adaptive immune response by priming naı ¨ve T lymphocytes
[13].
Cell-mediated immunity is essential for control of M. tuberculosis
infection; activation of both CD4
+ and CD8
+ T cells is seen in
active TB in humans, as well as in mice after experimental
infection [14]. CD4
+ T lymphocytes of T helper cell type 1(Th1)
are thought to be most critical [15]. Also, there is experimental
evidence that CD8
+ T cells [16,17], as well as unconventional T
cells such as CD1-restricted cells recognizing mycobacterial lipids
[18], contribute to optimal control of the disease. T cells recruited
to the infected lung are thought to control infection by producing
interferon gamma (IFN-c) in response to mycobacterial antigens
presented by macrophages [19,20]. In turn, IFN-c activates
macrophages to kill the intracellular bacteria through reactive
nitrogen and oxygen intermediates [21], and by inducing
phagolysosome formation [13]. However, these mechanisms might
even be present in susceptible hosts, in which the infection
progresses to disease. The full knowledge of the constituents of an
effective protective immune response to TB is still incomplete.
In the M. tuberculosis–infected host there is also a robust humoral
response, with a wide spectrum of antibodies (Abs) of different
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1specificities and isotypes; although secondary to the cellular
immune responses in terms of protection, B cells as well as certain
Ab responses have been shown to be capable of playing an
important role in protective immunity to TB [22].
Aspects of Immune Response to HIV Infection
HIV-1, which most commonly infects via the genital mucosa,
persists as a chronic infection event h o u g ht h ev i r u se l i c i t ss t r o n g
innate and adaptive, including cellular and humoral, immunity.
Explanations for this may be linked to virus genomic integration
and subsequent cellular latency, as well as an extreme genetic
variability, which translates into constant immune escape. HIV-
specific CD8
+ lymphocytes play a key role in the initial
reduction of viremia during acute infection, but become
increasingly dysfunctional and exhausted under conditions of
chronic antigen persistence [23,24]. Virus-neutralizing Abs are
also elicited but are frequently accompanied by immune escape,
and even if some individuals develop cross-neutralizing Abs, it is
debatable whether Abs play a role in the control of the virus
[25].
The hallmark of HIV infection is the depletion of CD4
+ T cells.
Interestingly, during the primary HIV infection, the cells that are
preferentially depleted are the effector memory CD4
+ T cells in
the gut mucosa [26]. These immunopathogenic features, together
with the systemic and chronic state of immune activation,
including accelerated T cell turnover, are thought to contribute
to progression of HIV disease [27]. Thus, constant antigenic
stimulation is characterized by a dysfunctional T cell population
displaying loss of functional potential, i.e., cytokine production and
cytotoxic activity, and proliferative ability in response to antigen
stimulation. In addition, the loss of immune balance between
Th17 and regulatory T cells (Treg) during HIV disease
progression has recently been implicated in permeabilization of
gut integrity and the pathogenesis of HIV [28].
Microbial translocation caused by gut permeability has also
been suggested to contribute to systemic immune activation
observed during chronic HIV infection [29]. Hyper-responsiveness
of plasmacytoid DCs during the primary infection, which results in
excessive type-1 IFN production and the following chronic
activation of these cells, may additionally contribute to systemic
immune activation and HIV-1 disease progression [30].
CD8
+ T cells have been implicated in the control of chronic
HIV replication as suggested by studies on simian immunodefi-
ciency virus (SIV) viremia in non-human primates after in vivo
CD8
+ T cell depletion [31]. In addition, there are rare individuals
who control HIV-1 replication to undetectable levels, i.e., elite
controllers. This phenotype is strongly associated with some MHC
class I alleles [32] and with the presence of HIV-specific CD8
+ T
cells showing superior cytotoxic capacity to kill HIV-infected
targets [33,34].
Programmed-Death 1 (PD-1) and T cell immunoglobulin and
mucin domain 3 (Tim-3) are two examples of markers of T cell
exhaustion in HIV-1
+ patients caused by constant antigenic
stimulation [35,36]. Both molecules are involved in the down-
regulation of host immune responses and play a role in
maintaining T cell tolerance. A recent finding is that Tim-3 was
up-regulated on virus-specific CD8
+ T cells in patients with
chronic progressive HIV infection [36]; another recent publication
reports that Tim-3 was up-regulated on antigen-specific CD8
+ T
cells in patients with active TB [37], indicating that similar
inhibitory receptor/ligand interactions play a role in modulating
host immunity to both HIV and M. tuberculosis infections in
humans.
TB Reactivation by HIV
It is generally thought that one-third of the world’s population is
latently infected with M. tuberculosis [38], although the data
supporting this notion may be questioned. Also, the rate of
progression from infection to disease varies greatly. Approximately
10% of M. tuberculosis–infected individuals are thought to develop
overt clinical disease [6] and about half of them develop disease
more than two years after infection; these cases are commonly
named ‘‘reactivation’’ or post-primary TB [39]. Thus, the lifetime
risk of developing active TB in immunocompetent adults is
estimated to be 5%–10% during their lifetime, but in HIV-positive
individuals this risk is increased to 5%–15% annually [40].
The depletion of CD4
+ T cells, which is a main feature of AIDS,
is certainly an important contributor to the increased risk of
reactivation of latent TB and susceptibility to new M. tuberculosis
infection. There is also some evidence that CD8
+ T cells play a
role in the control of latent TB [41–44]. Other mechanisms
reported to facilitate M. tuberculosis infection and disease in
individuals with HIV are up-regulation of M. tuberculosis entry
receptors on macrophages [45], HIV manipulation of macrophage
bactericidal pathways [46], deregulated chemotaxis [47], and a
tipped Th1/Th2 balance [48]. It has also been shown that HIV
impairs tumor necrosis factor (TNF)-mediated macrophage
apoptotic response to M. tuberculosis and thus facilitates bacterial
survival [49].
In the latent phase of TB, the bacteria are not completely
eradicated despite a seemingly robust Th1 immune response. A
failure or an alteration of the quality or levels of the protective
adaptive immune responses or of the cross-talk with innate
immune responses leads to reactivation of infection. Several
immune mechanisms, such as increased levels of FoxP3
+ Treg cells
[50], increased production of IL-27 [51], TGF-b [52,53], PGE-2
[54], SOCS1, or the decoy receptor D6 [55], or diminished levels
of IFN-c, TNF, and polyfunctional specific T cells, are believed to
play a role in such reactivation. Many of these factors, such as
SOCS1 or IL-27, down-regulate the IFN-c/IL-12 axis, thereby
impairing bacterial control, while others, such as the D6 decoy
receptor, are mainly anti-inflammatory, but may indirectly inhibit
efficient bacterial clearance. Some of these mechanisms may also
underlie HIV-infected patients’ increased susceptibility to active
TB.
Granulomas are organized cellular structures that constitute
TB’s pathologic hallmark. Mycobacteria are contained within the
granuloma, which, by localizing infection and thus potentially
preventing spread of the disease between hosts, probably
contributes to protection. CD4
+ T cells and TNF are important
in maintaining granuloma organization. Granuloma formation
may fail in individuals with a compromised immune system, and
there are several hypotheses about how HIV exacerbates TB
pathology through the manipulation of granulomas [56]. Specif-
ically, TB patients with AIDS present a dominant granulocytic
infiltrate and necrosis without the typical caseous necrosis seen in
non-HIV-infected TB granulomas. This has been associated with
the killing of CD4
+ cells in the granuloma, probably resulting in a
direct disruption of granuloma structure and abolition of the
containment of infection. Cavitary lesions are seldom encountered
in patients with a CD4 T-lymphocyte count ,200/mm
3 [57]. As a
result, while in the majority of adult patients TB is confined
preferentially to the lungs, in HIV-infected patients TB can be a
systemic disease involving multiple organs that lack well-defined
granulomas and instead develop more diffuse lesions [58]. All
forms of extrapulmonary TB have been described in patients with
HIV.
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anti-inflammatory T cell responses within the granuloma that may
have significant effects on reactivation of latent TB. Reduction of
T cell numbers also occurred within lung granulomas of monkeys
co-infected with SIV compared with monkeys exclusively infected
with TB [59]. It is important to note that besides the known
increased risk of disseminated disease in adults with HIV, there is a
growing recognition from prevalence surveys of subclinically active
TB infection in co-infected individuals [60].
Exacerbation of HIV Infection by M. tuberculosis
Infection
The incidence and mortality rates for new AIDS-defining
opportunistic infections have been shown to be higher if
individuals with HIV are co-infected with TB [7,61]. Despite
these epidemiological data supporting the notion that M.
tuberculosis infection has a negative impact on the immune response
to HIV and on progression to AIDS, research on possible
mechanisms is scarce. The function of many immune cells,
including macrophages and DCs, is modulated by both HIV and
M. tuberculosis. Increased replication of the virus was demonstrated
locally, at sites of M. tuberculosis infection in the lung [62], and
within activated cells, including lymphocytes and CD14
+ macro-
phages, of the pleural space [63] of co-infected patients. M.
tuberculosis has been reported to up-regulate HIV-1 replication in
chronically or acutely infected T cells or macrophages [64,65], as
well as ex vivo in alveolar macrophages and lymphocytes from
patients with HIV [66,67]. These in vitro/ex vivo findings are also
reflected in vivo where elevated plasma viral loads have been
detected in HIV-infected individuals with concomitant active TB
disease [68].
The primary target for M. tuberculosis, the alveolar macro-
phage, can also be infected with HIV [69–71]. Mycobacteria
exacerbate HIV replication in macrophages and lung cells
obtained by bronchoalveolar lavage from co-infected individuals
[62,65,72]. Also, in vitro studies have demonstrated that M.
tuberculosis infection can up-regulate both HIV infection and
replication within monocyte-derived macrophages (MDMs),
increase the efficiency of virus transmission from infected MDMs
to T cells, and favor replication of X4 HIV variants by up-
regulation of CXCR4 [73]. Furthermore, monocytes from HIV
+
patients display an impaired response to TLR ligands [74], and
viral proteins can interfere with both MDM and DC maturation
and function in vitro, including their ability to phagocytose
mycobacteria and kill intracellular bacteria [75–78]. SOCS1,
which is stimulated by infection with M. tuberculosis [45], has been
shown to facilitate the late replication pathways of HIV infection
[79] and mediate viral evasion of type I IFN anti-viral signalling
[80].
While TNF production in response to M. tuberculosis infection is
required for control of bacterial growth, TNF is known to activate
HIV replication in macrophages [81], indicating that the host
immune response initiated against one pathogen may promote the
replication of another. Thus, both HIV and M. tuberculosis
stimulate TNF release from infected cells, and TNF hampers
bacterial growth while enhancing HIV replication.
M. tuberculosis survives in DCs and actively down-regulates their
pro-inflammatory activity and antigen-presenting function, with
concurrent induction of anti-inflammatory cytokines [82]. Simi-
larly, HIV can infect and also manipulate DCs and the ensuing T
cell functions [83]. In HIV infection, not only is DC-mediated
activation of T cells impaired, but the migration of infected DCs
can also contribute to pathogen dissemination.
The DC-expressed C-type lectin receptor DC-SIGN (DC-
specific intercellular-adhesion-molecule-3-grabbing nonintegrin)
has been suggested to facilitate transmission and immune escape
of both M. tuberculosis and HIV [84]. HIV attaches to DC-SIGN
through interaction with the viral envelope glycoprotein gp120,
and this interaction is thought to contribute to efficient spread and
transmission of the virus to CD4
+ T cells in trans [85,86]. M.
tuberculosis has been reported to target DC-SIGN by a mechanism
that is distinct from that of HIV, leading to inhibition of pro-
inflammatory IL-12 and TNF production and induction of IL-10
by DCs [87] and, hence, down-regulation of protective immune
responses.
It has been suggested that TB patients have a microenviron-
ment that facilitates HIV infection by i) increasing the expression
of co-receptors CXCR4 and CCR5 regulated by M. tuberculosis
products; ii) increasing pro-inflammatory cytokines, especially
TNF; and iii) down-regulation of CCL5 [45]. It has also been
shown that M. tuberculosis and its cell wall component, lipoar-
abinomannan (LAM) [88], may activate replication of HIV in
provirus-carrying cells by inducing TNF and IL-6 production
through the NF-kB pathway, which in turn triggers transcriptional
activation of the long terminal repeat (LTR) promoter and
supports replication of HIV [5].
Immune Reconstitution Inflammatory Syndrome
A particularly intriguing phenomenon is immune reconstitution
inflammatory syndrome (IRIS). IRIS may develop in M. tuberculosis
and HIV co-infected patients who undergo anti-TB treatment and
antiretroviral therapy (ART) [89,90]. The definition of IRIS in
TB/HIV co-infected patients is still debated [91]. The patients
present with an exacerbation of symptoms and radiological
manifestations of TB, and recognized predictors of IRIS include
low CD4
+ T lymphocyte counts and high plasma viral load prior
to initiation of ART, and an increase in CD4
+ counts after highly
active antiretroviral therapy (HAART) onset [92]. Possible
mechanisms responsible for IRIS may be a sustained Th1-
response against mycobacterial antigens, which is followed by
dysregulation of cytokine secretion and T cell migration to the
inflammatory site [93]. Recently, it was shown that patients who
developed IRIS had higher pre-ART levels of TNF and increasing
levels of inflammation biomarkers [94]. Moreover, it has been
demonstrated that TB/HIV co-infected patients who experienced
IRIS had significantly lower levels of Abs to the phenolic glycolipid
(PGL-TB1) antigen, specific for M. tuberculosis, compared to
patients who did not develop TB-IRIS [95].
Animal Models to Study M. tuberculosis and HIV
Co-Infection
One of the most important challenges in studies of co-infection
is to identify appropriate animal models, since HIV does not cause
disease in rodents or even non-human primates. Thus, while mice
are ideal models to study immune response to infection and
vaccination due to the large diversity of tools and knowledge about
their immune system, conventional mice are not susceptible to
HIV infection owing to the restricted specificity of the virus for the
human cell. To circumvent this limitation, two complementary
mouse models were recently generated. Using these models, the
most relevant features of M. tuberculosis and HIV infections can be
reproduced in mice (e.g., typical TB granuloma formation; virus
replication in splenic lymphocytes, peritoneal macrophages, and
brain; immune exhaustion and/or chronic immune activation;
and susceptibility to systemic, vaginal, and rectal HIV infection).
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cells (CD34
+) from human cord blood are used to reconstitute the
immune system of immunodeficient mice [96]. A variation of this
model incorporates the engraftment of a fetal human thymus
fragment, which gains activity as a functional human thymus,
allowing a more proper positive and negative T cell selection than
the original model [97]. Features such as CD4
+ cell depletion,
prolonged viremia, and co-receptor-mediated tropism were
observed during HIV infection of humanized mice [97–101].
These mice show transplanted human cells in mucosal surfaces
and could thereby be infected by the intravaginal and intrarectal
routes [102]. The model has been used to evaluate new
approaches to the prevention or treatment of HIV infection,
including human-neutralizing Abs [102], prophylactic usage of
antiretrovirals [98], and T cell–specific siRNA delivery [103].
Inoculation of humanized mice with mycobacteria enhances the
CD4/CD8 cell ratio, the differentiation of CD4
+ cells into
memory/effector types, and the translocation of IFN-c-secreting
T cells into the lung. Of particular importance is that lungs and
livers from infected mice show typical features of mycobacterial
granuloma (F. Heuts, D. Gavier Wide ´n, B. Carow, J. Juarez, H.
Wigzell, et al., unpublished data). On the negative side, the
adaptive immune responses, especially the specific IgG levels in
response to immunization or infection, are low.
The other mouse model used to study M. tuberculosis/HIV
interaction, the ‘‘EcoHIV’’ model, makes use of a modified HIV-1
strain, in which the coding region of gp120 has been replaced by
that of gp80 from ecotropic murine leukemia virus, that is able to
infect the immune cells of conventional mice [104]. The resulting
chimeric virus construct, EcoHIV, productively infects immuno-
competent mice. Replicating virus is detected in splenic lympho-
cytes, peritoneal macrophages, and the brain of mice. The
chimeric virus also elicits an immune response directed against
viral proteins, and stimulates mouse genes similar to those
stimulated by HIV in humans. This murine model of HIV
infection has proven useful in vaccine challenge studies and for
preclinical evaluation of antiretroviral drugs [105–107].
HIV transgenic mice incorporating the entire viral genome have
also been used to study the effect of M. tuberculosis infection on the
induction of HIV gene expression [108]. In this model, viral gene
expression was activated by M. tuberculosis and suppressed after
anti-mycobacterial chemotherapy [108].
Although non-human primates are resistant to infection by
HIV, they can be infected by SIV, a retrovirus causing
immunodeficiency similar to AIDS in Asian macaques. Thus,
SIV infection in macaques has been used as a model for AIDS.
Macaques also develop TB that is very similar to TB in humans,
and can develop cavitary lung disease and necrotic lesions. They
also can maintain TB latency for years, and only a small
proportion of latently infected macaques develop reactivation
[56]. Macaques infected with SIV can develop persistent
Mycobacterium bovis bacillus Calmette Guerin (BCG) [109] and M.
tuberculosis co-infection [59,110]. Co-infection with SIV and BCG
accelerated progression to AIDS [111] and coincided with a severe
depletion of CD4
+ T cells, loss of BCG-specific T cell responses,
and reactivation of the clinically latent BCG infection into a TB-
like disease [112]. M. tuberculosis reactivation in SIV-infected
macaques is associated with early peripheral T cell depletion and
not virus load [59].
Summary and Perspectives
TB/HIV co-infection represents a novel pathogenic scenario at
the global level. It constitutes a serious diagnostic and therapeutic
challenge and, particularly in poor countries, weighs heavily on
already strained health care budgets. It has recently been realized
that the epidemiology, clinical manifestations, and management of
both HIV and M. tuberculosis infections are different and far more
complex in co-infected compared to mono-infected patients.
However, our knowledge about the mechanisms of interaction of
the two pathogens still has many gaps that need to be filled in order
to develop preventive measures against the two diseases (Box 1).
Ultimately, the most cost-effective way of combating the two
diseases would be vaccination. The present TB vaccine, BCG,
does not effectively prevent the most prevalent form of the disease,
pulmonary TB in adults. Similarly, no effective, preventive HIV
vaccine can be discerned on the horizon, although many vaccine
candidates are being evaluated in clinical trials. One approach
would be to construct a combined TB/HIV vaccine [113], such as
a recombinant BCG vaccine as a vehicle for combinations of
mycobacterial and HIV antigens.
The design of candidate vaccines is, however, a particularly
difficult task since laboratory correlates of protection have not
been defined for M. tuberculosis and HIV infections. In addition,
vaccine-induced immune responses need to be tipped towards
protection, avoiding those that may result in immunopathology;
this requires meticulous study of appropriate adjuvants, antigens,
and vaccination regimens for the novel vaccines. Here the
immunomodulatory role of individual antigens of the two
pathogens needs further elucidation. For example, the major
HIV antigen gp120 [114] and mycobacterial compounds such as
glycolipids of the cell wall, particularly LAMs, PIMs, and phenolic
glycolipids [115], play a crucial role in modulating immune
responses. It is also increasingly apparent that these compounds
may differ in biologic activity depending on strain lineages of the
two pathogens [53,115,116].
Since both pathogens enter the host through mucosal surfaces, a
combination vaccine given at mucosal sites would probably be
optimal [117–119]. However, for this, further research in the
biology of concurrent M. tuberculosis and HIV infections is urgently
needed, using in vitro systems, animal models, and clinical studies,
as well as vaccine trials.
Box 1. Scientific and Technological Objectives
for Integrating Knowledge in the Field of Co-
Infections with HIV and M. tuberculosis
N Development of standardized in vitro and in vivo models
for studies of co-infections
N Interactions and receptor signalling in dendritic cells
N HIV/M. tuberculosis-specific T/B cell responses
N Role of memory T cells in the maintenance of latent
infection and of regulatory T cells in disease outbreak
N Effector mechanisms of T cells involved in protection
against TB
N The role of antimicrobial peptides in cytolytic T cells
N Regulation of T cell differentiation during co-infection
N Immunological synapse; interactions of T and antigen-
presenting cells
N Mathematical modelling and simulation of T, B, and NK
cell repertoires
N Mechanisms of HIV–TB interactions in IRIS
N The role of individual HIV/M. tuberculosis antigens/
molecules in immunopathology
N Effect on immune response in infected individuals after
vaccination with TB and/or HIV vaccine candidates
PLoS Pathogens | www.plospathogens.org 4 February 2012 | Volume 8 | Issue 2 | e1002464Thus, an integrated approach to the two diseases should lead to
novel concepts and correlates of protection and to the identifica-
tion of antigen targets useful for new therapies to overcome the
rapidly increasing drug resistance of both diseases, as well as for
vaccination.
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